Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663 · see citing works

Clinical Effect of Point Mutations in Myelodysplastic Syndromes

Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627 · see citing works

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061292 · Cited by 1,319 · see citing works

p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies

Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P., & Fenaux, P. (1994) · Blood · doi:10.1182/blood.v84.9.3148.3148 · Cited by 592 · see citing works

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

Fenaux, P., Giagounidis, A. A. N., Selleslag, D., Beyne‐Rauzy, O., Mufti, G. J., Mittelman, M., Muus, P., Boekhorst, P. A. W. T., Sanz, G. F., del Cañizo, C., et al. (2011) · Blood · doi:10.1182/blood-2011-01-330126 · Cited by 488 · see citing works

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

Itzykson, R., Kosmider, O., Cluzeau, T., Mas, V. M., Dreyfus, F., Beyne‐Rauzy, O., Quesnel, B., Vey, N., Gelsi‐Boyer, V., Raynaud, S., et al. (2011) · Leukemia · doi:10.1038/leu.2011.71 · Cited by 470 · see citing works

<i>TP53</i> Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

Jädersten, M., Saft, L., Smith, A., Kulasekararaj, A., Pomplun, S., Göhring, G., Hedlund, A., Hast, R., Schlegelberger, B., Porwit, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8576 · Cited by 463 · see citing works

A simple p53 functional assay for screening cell lines, blood, and tumors.

Flaman, J., Frébourg, T., Moreau, V., Charbonnier, F., Martin, C., Chappuis, P. O., Sappino, A. P., Limacher, I. M., Bron, L. P., & Benhattar, J. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3963 · Cited by 455 · see citing works

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine

Itzykson, R., Thépot, S., Quesnel, B., Dreyfus, F., Beyne‐Rauzy, O., Turlure, P., Vey, N., Récher, C., Dartigeas, C., Legros, L., et al. (2010) · Blood · doi:10.1182/blood-2010-06-289280 · Cited by 381 · see citing works

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.

Shen, L.-L., Kantarjian, H., Guo, Y., Lin, E., Shan, J., Huang, X., Berry, D., Ahmed, S. S., Zhu, W., Pierce, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4781 · Cited by 348 · see citing works

Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes

Bejar, R. L., Levine, R. L., & Ebert, B. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1175 · Cited by 303 · see citing works

<i> <scp>TP</scp> 53 </i> mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis

Kulasekararaj, A. G., Smith, A. E., Mian, S. A., Mohamedali, A. M., Krishnamurthy, P., Lea, N. C., Gäken, J., Pennaneach, C., Ireland, R., Czepulkowski, B., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12203 · Cited by 250 · see citing works

Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype

Haferlach, C., Dicker, F., Herholz, H., Schnittger, S., Kern, W., & Haferlach, T. (2008) · Leukemia · doi:10.1038/leu.2008.143 · Cited by 247 · see citing works

Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.

Laï, J., Preudhomme, C., Zandecki, M., FLACTIF, M., Vanrumbeke, M., Lepelley, P., Wattel, E., & Fenaux, P. (1995) · PubMed · Cited by 197 · see citing works

Activation of the p53 DNA Damage Response Pathway after Inhibition of DNA Methyltransferase by 5-Aza-2′-deoxycytidine

Karpf, A. R., Moore, B. C., Ririe, T. O., & Jones, D. A. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.4.751 · Cited by 176 · see citing works

High Frequency of TP53 Mutation in BRCA1 and Sporadic Basal-like Carcinomas but not in BRCA1 Luminal Breast Tumors

Manié, É., Vincent‐Salomon, A., Lehmann‐Che, J., Pierron, G., Turpin, E., Warcoin, M., Gruel, N., Lebigot, I., Sastre‐Garau, X., Lidereau, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1560 · Cited by 149 · see citing works

17p Deletion in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Analysis of Breakpoints and Deleted Segments by Fluorescence In Situ

Soenen, V., Preudhomme, C., Roumier, C., Daudignon, A., Laı̈, J. L., & Fenaux, P. (1998) · Blood · doi:10.1182/blood.v91.3.1008 · Cited by 134 · see citing works

Mutations in the p53 gene in myelodysplastic syndromes.

Jonveaux, P., Fenaux, P., Quiquandon, I., Jm, P., Laı̈, J. L., Mh, L.-L., Goossens, M., Bauters, F., & Berger, R. (1991) · PubMed · Cited by 121 · see citing works

Mutations of the P53 gene in acute myeloid leukaemia

Fenaux, P., Preudhomme, C., Quiquandon, I., Jonveaux, P., Laı̈, J. L., Vanrumbeke, M., Loucheux‐Lefebvre, M. H., Bauters, F., Berger, R., & Kerckaert, J. P. (1992) · British Journal of Haematology · doi:10.1111/j.1365-2141.1992.tb08897.x · Cited by 117 · see citing works

Sustained exposure to the DNA demethylating agent, 2′-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy

Schnekenburger, M., Grandjenette, C., Ghelfi, J., Karius, T., Foliguet, B., Dicato, M. A., & Diederich, M. F. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.10.013 · Cited by 100 · see citing works

The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories

Kohlmann, A., Klein, H.-U., Weißmann, S., Bresolin, S., Chaplin, T., Cuppens, H., Haschke‐Becher, E., Garicochea, B., Grossmann, V., Hanczaruk, B., et al. (2011) · Leukemia · doi:10.1038/leu.2011.155 · Cited by 100 · see citing works

Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression

Oshiro, M. M., Watts, G. S., Wozniak, R. J., Junk, D. J., Muñoz-Rodríguez, J. L., Domann, F. E., & Futscher, B. W. (2003) · Oncogene · doi:10.1038/sj.onc.1206545 · Cited by 98 · see citing works

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

Kelaïdi, C., Park, S., Sapena, R., Beyne‐Rauzy, O., Coiteux, V., Vey, N., Stamatoullas, A., Choufi, B., Delaunay, J., Gourin, M. P., et al. (2013) · Leukemia · doi:10.1038/leu.2013.16 · Cited by 69 · see citing works

The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience

Lamarque, M., Raynaud, S., Itzykson, R., Thépot, S., Quesnel, B., Dreyfus, F., Beyne‐Rauzy, O., Turlure, P., Vey, N., Récher, C., et al. (2012) · Blood · doi:10.1182/blood-2012-09-453555 · Cited by 52 · see citing works

5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand

Ghanim, V., Herrmann, H., Heller, G., Peter, B., Hadzijusufovic, E., Blatt, K., Schuch, K., Cerny‐Reiterer, S., Mirkina, I. I., Karlic, H., et al. (2012) · Blood · doi:10.1182/blood-2011-09-382770 · Cited by 38 · see citing works

Mutations of TP53 induce loss of DNA methylation and amplification of the TROP1 gene

Nasr, A. F., Nutini, M., Palombo, B., Guerra, E., & Alberti, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206248 · Cited by 36 · see citing works

Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine

Itzykson, R., Thépot, S., Éclache, V., Quesnel, B., Dreyfus, F., Beyne‐Rauzy, O., Turlure, P., Vey, N., Récher, C., Boehrer, S., et al. (2011) · Leukemia · doi:10.1038/leu.2011.63 · Cited by 36 · see citing works

Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDS

Traina, F., Jankowska, A. M., Visconte, V., Sugimoto, Y., Szpurka, H., Makishima, H., Jerez, A., O’Keefe, C. L., Sekeres, M. A., Advani, A. S., et al. (2011) · Blood · doi:10.1182/blood.v118.21.461.461 · Cited by 27 · see citing works

Inactivation of the p53 gene in leukemias and myelodysplastic syndrome (MDS) with 17p monosomy.

Preudhomme, C., Vanrumbeke, M., Laï, J., Lepelley, P., Wattel, E., & Fenaux, P. (1994) · PubMed · Cited by 10 · see citing works

Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation

Lindsley, R. C., Saber, W., Mar, B. G., Redd, R., Wang, T., Haagenson, M. D., Grauman, P. V., Hu, Z.-H., Spellman, S. R., Lee, S. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611604 · Cited by 776 · see citing works

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

Bejar, R. L., Lord, A. M., Stevenson, K. E., Bar‐Natan, M., Pérez-Ladaga, A., Zaneveld, J. E., Wang, H., Caughey, B. A., Stojanov, P., Getz, G. A., et al. (2014) · Blood · doi:10.1182/blood-2014-06-582809 · Cited by 563 · see citing works

Eprenetapopt (APR-246) and Azacitidine in <i>TP53</i> -Mutant Myelodysplastic Syndromes

Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A., Cluzeau, T., Sweet, K. L., McLemore, A., McGraw, K. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02341 · Cited by 465 · see citing works

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Walker, B. A., Mavrommatis, K., Wardell, C. P., Ashby, C., Bauer, M., Davies, F. E., Rosenthal, A., Wang, H., Qu, P., Hoering, A., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0196-8 · Cited by 445 · see citing works

Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy

Kang, J., Brajanovski, N., Chan, K. T., Xuan, J., Pearson, R. B., & Sanij, E. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00728-8 · Cited by 412 · see citing works

Eprenetapopt Plus Azacitidine in <i>TP53</i> -Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)

Cluzeau, T., Sebert, M., Rahmé, R., Cuzzubbo, S., Lehmann-Che, J., Madelaine, I., Peterlin, P., Bève, B., Attalah, H., Chermat, F., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02342 · Cited by 279 · see citing works

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups

for the International Working Group for MDS Molecular Prognostic Committee, Haase, D., Stevenson, K. E., Neuberg, D., Maciejewski, J. P., Nazha, A., Sekeres, M. A., Ebert, B. L., Garcia-Manero, G., Haferlach, C., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0351-2 · Cited by 259 · see citing works

Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes

Sallman, D. A., Komrokji, R., Vaupel, C., Cluzeau, T., Geyer, S. M., McGraw, K. L., Al Ali, N. H., Lancet, J., McGinniss, M. J., Nahas, S., et al. (2016) · Leukemia · doi:10.1038/leu.2015.304 · Cited by 231 · see citing works

Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management

Garcia‐Manero, G. (2023) · American Journal of Hematology · doi:10.1002/ajh.26984 · Cited by 230 · see citing works

Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management

Bravo, G. M., & Garcia‐Manero, G. (2017) · American Journal of Hematology · doi:10.1002/ajh.24930 · Cited by 205 · see citing works

Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management

Garcia‐Manero, G., Chien, K. S., & Bravo, G. M. (2020) · American Journal of Hematology · doi:10.1002/ajh.25950 · Cited by 187 · see citing works

Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions

Valent, P., Orazi, A., Savona, M. R., Patnaik, M. M., Onida, F., van de Loosdrecht, A. A., Haase, D. T., Haferlach, T., Elena, C., Pleyer, L., et al. (2019) · Haematologica · doi:10.3324/haematol.2019.222059 · Cited by 141 · see citing works

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Montalban-Bravo, G., Kanagal-Shamanna, R., Benton, C. B., Class, C. A., Chien, K. S., Sasaki, K., Naqvi, K., Alvarado, Y., Kadia, T. M., Ravandi, F., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001101 · Cited by 133 · see citing works

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

Short, N. J., Kantarjian, H. M., Loghavi, S., Huang, X., Qiao, W., Borthakur, G., Kadia, T. M., Daver, N., Ohanian, M., Dinardo, C. D., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30182-0 · Cited by 120 · see citing works

The molecular pathogenesis of the myelodysplastic syndromes

Pellagatti, A., & Boultwood, J. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12515 · Cited by 116 · see citing works

Mutations of myelodysplastic syndromes (MDS): An update

Ganguly, B. B., & Kadam, N. N. (2016) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2016.04.009 · Cited by 105 · see citing works

Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes

Garcia‐Manero, G., Montalban‐Bravo, G., Berdeja, J. G., Abaza, Y., Jabbour, E., Essell, J., Lyons, R. M., Ravandi, F., Maris, M., Heller, B., et al. (2017) · Cancer · doi:10.1002/cncr.30533 · Cited by 104 · see citing works

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

Takahashi, K., Patel, K. P., Bueso-Ramos, C., Zhang, J., Gumbs, C. E., Jabbour, E. J., Kadia, T. M., Andreff, M., Konopleva, M. Y., Dinardo, C. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7290 · Cited by 101 · see citing works

TP 53 mutation in patients with high‐risk acute myeloid leukaemia treated with allogeneic haematopoietic stem cell transplantation

Middeke, J. M., Herold, S., Rücker‐Braun, E., Berdel, W. E., Stelljes, M., Kaufmann, M., Schäfer‐Eckart, K., Baldus, C. D., Stuhlmann, R., Ho, A. D., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13912 · Cited by 98 · see citing works

Pharmacological reactivation of p53 in the era of precision anticancer medicine

Tuval, A., Strandgren, C., Heldin, A., Palomar-Siles, M., & Wiman, K. G. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00842-2 · Cited by 84 · see citing works

Novel drugs for older patients with acute myeloid leukemia

Bravo, G. M., & Garcia‐Manero, G. (2014) · Leukemia · doi:10.1038/leu.2014.244 · Cited by 82 · see citing works

What have we learned about TP53-mutated acute myeloid leukemia?

Shahzad, M., Amin, M. K., Daver, N. G., Shah, M. V., Hiwase, D., Arber, D. A., Kharfan‐Dabaja, M. A., & Badar, T. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01186-5 · Cited by 83 · see citing works

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes

Hunter, A. M., Komrokji, R. S., Yun, S., Al Ali, N., Chan, O., Song, J., Hussaini, M., Talati, C., Sweet, K. L., Lancet, J. E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003508 · Cited by 76 · see citing works

The genetic and molecular pathogenesis of myelodysplastic syndromes

Shallis, R. M., Ahmad, R., & Zeidan, A. M. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13092 · Cited by 74 · see citing works

Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature

Kuendgen, A., Müller‐Thomas, C., Lauseker, M., Haferlach, T., Urbaniak, P., Schroeder, T. A., Brings, C., Wulfert, M., Meggendorfer, M., Hildebrandt, B., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25328 · Cited by 73 · see citing works

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?

Molica, M., Mazzone, C., Niscola, P., & de Fabritiis, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.610820 · Cited by 71 · see citing works

Acute Myeloid Leukemia With Myelodysplasia-Related Changes

Vardiman, J. W., & Reichard, K. K. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcp58rsmfrhlhhh · Cited by 70 · see citing works

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome

Jung, S., Kim, Y., Yim, S., Kim, H. J., Kwon, Y.-R., Hur, E., Goo, B.-K., Choi, Y., Lee, S. H., Chung, Y., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10526 · Cited by 68 · see citing works

Guadecitabine (SGI-110): an investigational drug for the treatment of myelodysplastic syndrome and acute myeloid leukemia

Daher-Reyes, G. S., Merchán, B., & Yee, K. W. L. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1667331 · Cited by 66 · see citing works

Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Poiré, X., Labopin, M., Maertens, J. A., Yakoub‐Agha, I., Blaise, D., Ifrah, N., Socié, G., Gedde-Dhal, T., Schaap, N. P., Cornelissen, J. J., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0393-3 · Cited by 59 · see citing works

Clinical decision-making and treatment of myelodysplastic syndromes

Hellström‐Lindberg, E., & Kröger, N. M. (2023) · Blood · doi:10.1182/blood.2023020079 · Cited by 59 · see citing works

TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes

Beličková, M., Veselá, J., Jonasova, A. T., Pejsova, B., Votavová, H., Merkerová, M. D., Zemanová, Z., Březinová, J., Mikulenková, D., Lauermannová, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9200 · Cited by 56 · see citing works

Hypomethylating Agents as a Therapy for AML

Gardin, C., & Dombret, H. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0363-4 · Cited by 57 · see citing works

Azacitidine in adult patients with acute myeloid leukemia

Schuh, A. C., Döhner, H., Pleyer, L., Seymour, J. F., Fenaux, P., & Dombret, H. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.05.010 · Cited by 56 · see citing works

Decitabine inTP53-Mutated AML

Welch, J. S., Petti, A. A., & Ley, T. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1616062 · Cited by 56 · see citing works

TP 53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis

Loghavi, S., Al‐Ibraheemi, A., Zuo, Z., Garcia‐Manero, G., Yabe, M., Wang, S. A., Kantarjian, H. M., Yin, C. C., Miranda, R. N., Luthra, R., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13529 · Cited by 51 · see citing works

Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline

de Haas, V., Ismaila, N., Advani, A. S., Arber, D. A., Dabney, R. S., Patel‐Donnelly, D., Kitlas, E., Pieters, R., Pui, C., Sweet, K. L., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01468 · Cited by 51 · see citing works

Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)

Yun, S., Geyer, S. M., Komrokji, R. S., Al Ali, N. H., Song, J., Hussaini, M., Sweet, K. L., Lancet, J. E., List, A. F., Padron, E., et al. (2021) · Leukemia · doi:10.1038/s41375-020-0997-4 · Cited by 49 · see citing works

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation

George, B., Kantarjian, H. M., Baran, N., Krocker, J. D., & Rios, A. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910782 · Cited by 50 · see citing works

TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms

Shah, M. V., Tran, E. N. H., Shah, S., Chhetri, R., Baranwal, A., Ładoń, D., Shultz, C. T., Al‐Kali, A., Brown, A. L., Chen, D., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00821-x · Cited by 48 · see citing works

Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53- mutated MDS/AML

Nawas, M. T., & Kosuri, S. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010417 · Cited by 47 · see citing works

TP53 Mutation in Acute Myeloid Leukemia: An Old Foe Revisited

Shin, D.-Y. (2023) · Cancers · doi:10.3390/cancers15194816 · Cited by 46 · see citing works

Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond

Talati, C., Sallman, D. A., & List, A. F. (2017) · Seminars in Hematology · doi:10.1053/j.seminhematol.2017.06.003 · Cited by 44 · see citing works

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes

Cedena, M., Rapado, I., Santos‐Lozano, A., Ayala, R. M., Onecha, E., Abáigar, M., Such, E., Ramos, F., Cervera, J., Díez‐Campelo, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22157 · Cited by 42 · see citing works

A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death

Ceder, S., Eriksson, S. E., Cheteh, E. H., Dawar, S., Corrales Benitez, M., Bykov, V. J. N., Fujihara, K. M., Grandin, M., Li, X., Ramm, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.201910852 · Cited by 41 · see citing works

Integrating mutation variant allele frequency into clinical practice in myeloid malignancies

Sallman, D. A., & Padron, E. (2016) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2016.04.003 · Cited by 38 · see citing works

Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin

Wang, Y., Liu, Y., Bailey, C., Zhang, H., He, M., Sun, D., Zhang, P., Parkin, B., Baer, M. R., Zheng, P., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1201-z · Cited by 38 · see citing works

Overexpression of GYS1, MIF, and MYC Is Associated With Adverse Outcome and Poor Response to Azacitidine in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Falantes, J. F., Trujillo, P., Piruat, J. I., Calderón, C., Márquez-Malaver, F. J., Martín-Antonio, B., Millán‐Uclés, Á., Gómez, M., González, J., Martino, M. L., et al. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.10.003 · Cited by 38 · see citing works

An miRNA–DNMT1 Axis Is Involved in Azacitidine Resistance and Predicts Survival in Higher-Risk Myelodysplastic Syndrome and Low Blast Count Acute Myeloid Leukemia

Solly, F., Koering, C., Mohamed, A. M., Maucort‐Boulch, D., Robert, G., Auberger, P., Flandrin‐Gresta, P., Adès, L., Fenaux, P., Kosmider, O., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2304 · Cited by 37 · see citing works

Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status

Aldoss, I. T., Pham, A. T., Li, S. M., Gendzekhadze, K., Afkhami, M., Telatar, M., Hong, H., Padeganeh, A., Bedell, V., Cao, T. M., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.172544 · Cited by 36 · see citing works

TP53 in Myelodysplastic Syndromes: Recent Biological and Clinical Findings

Cumbo, C., Tota, G., Anelli, L., Zagaria, A., Specchia, G., & Albano, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103432 · Cited by 38 · see citing works

Significance of oncogenes and tumor suppressor genes in AML prognosis

Kavianpour, M., Ahmadzadeh, A., Shahrabi, S., & Saki, N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5067-1 · Cited by 36 · see citing works

Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies

Komrokji, R. S., Swern, A. S., Grinblatt, D. L., Lyons, R. M., Tobiasson, M., Silverman, L. R., Sayar, H., Vij, R., Fliss, A., Tu, N., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0215 · Cited by 36 · see citing works

TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms

Schimmer, R. R., Kovtonyuk, L. V., Klemm, N., Fullin, J., Stolz, S. M., Mueller, J. O., Caiado, F., Kurppa, K. J., Ebert, B. L., Manz, M. G., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005859 · Cited by 34 · see citing works

Opportunities and challenges for anti-CD47 antibodies in hematological malignancies

Xu, Y., Jiang, P., Xu, Z., & Ye, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1348852 · Cited by 33 · see citing works

Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes

Wang, H., Li, Y., Lv, N., Li, Y., Wang, L., & Yu, L. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3464-9 · Cited by 32 · see citing works

Acute Myeloid Leukemia Treatment in the Elderly: A Comprehensive Review of the Present and Future

Choi, J., Shukla, M., & Abdul‐Hay, M. (2023) · Acta Haematologica · doi:10.1159/000531628 · Cited by 31 · see citing works

TP53 Mutations in AML Patients Are Associated with Dismal Clinical Outcome Irrespective of Frontline Induction Regimen and Allogeneic Hematopoietic Cell Transplantation

Zhao, D., Zarif, M., Zhou, Q., Capo‐Chichi, J., Schuh, A. C., Minden, M. D., Atenafu, E. G., Kumar, R., & Chang, H. (2023) · Cancers · doi:10.3390/cancers15123210 · Cited by 29 · see citing works

Targeting TP53-Mutated Acute Myeloid Leukemia: Research and Clinical Developments

Granowicz, E. M., & Jonas, B. A. (2022) · OncoTargets and Therapy · doi:10.2147/ott.s265637 · Cited by 28 · see citing works

Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms

Nannya, Y., Tobiasson, M., Sato, S., Bernard, E., Ohtake, S., Takeda, J., Creignou, M., Zhao, L., Kusakabe, M., Shibata, Y., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009564 · Cited by 29 · see citing works

Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms

Lee, W., Lin, C., Tsai, C., Tien, F., Lo, M., Tseng, M., Kuo, Y., Yu, S., Liu, M.-C., Yuan, C., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01031-9 · Cited by 30 · see citing works

Chronic myelomonocytic leukemia - a review

Thomopoulos, T. P., Bouhla, A., Papageorgiou, S. G., & Pappa, V. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2021.1860004 · Cited by 27 · see citing works

Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial

Duong, V. H., Ruppert, A. S., Mims, A. S., Borate, U., Stein, E. M., Baer, M. R., Stock, W., Kovacsovics, T. J., Blum, W. G., Arellano, M. L., et al. (2023) · Cancer · doi:10.1002/cncr.34780 · Cited by 27 · see citing works

Potential Relationship between Inadequate Response to DNA Damage and Development of Myelodysplastic Syndrome

Zhou, T., Chen, P., Gu, J. H., Bishop, A. J. R., Scott, L., Hasty, P., & Rebel, V. I. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16010966 · Cited by 26 · see citing works

The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms

Briest, F., & Grabowski, P. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.03.006 · Cited by 26 · see citing works

Utx loss causes myeloid transformation

Zheng, L., Xu, L., Xu, Q., Yu, L., Zhao, D., Chen, P., Wang, W., Wang, Y., Han, G., & Chen, C. D. (2018) · Leukemia · doi:10.1038/s41375-018-0011-6 · Cited by 26 · see citing works

PP2A: The Achilles Heal in MDS with 5q Deletion

Sallman, D. A., Sheng, W., & List, A. F. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00264 · Cited by 25 · see citing works

Induction of senescence in cancer cells by 5′-Aza-2′-deoxycytidine: Bioinformatics and experimental insights to its targets

Putri, J. F., Widodo, N., Sakamoto, K., Kaul, S. C., & Wadhwa, R. (2017) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2017.08.003 · Cited by 25 · see citing works

Characterization of TP 53 mutations in low‐grade myelodysplastic syndromes and myelodysplastic syndromes with a non‐complex karyotype

Wang, W., Routbort, M. J., Tang, Z., Ok, C. Y., Patel, K. P., Daver, N. G., Garcia‐Manero, G., Medeiros, L. J., & Wang, S. A. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12971 · Cited by 24 · see citing works

British Society for Haematology guidelines for the management of adult myelodysplastic syndromes

Killick, S. B., Ingram, W. A., Culligan, D. J., Enright, H., Kell, J., Payne, E. M., Krishnamurthy, P., Kulasekararaj, A. G., Raghavan, M., Stanworth, S. J., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17612 · Cited by 25 · see citing works

Depletion of ZBTB38 potentiates the effects of DNA demethylating agents in cancer cells via CDKN1C mRNA up-regulation

Marchal, C., de Dieuleveult, M., Saint‐Ruf, C., Guinot, N., Ferry, L., Saad, S. T. O., Lazarini, M., Defossez, P., & Miotto, B. (2018) · Oncogenesis · doi:10.1038/s41389-018-0092-0 · Cited by 23 · see citing works

Targeting TP53 Mutations in Myelodysplastic Syndromes

Hunter, A. M., & Sallman, D. A. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.11.004 · Cited by 24 · see citing works

Can we predict responsiveness to hypomethylating agents in AML?

Stomper, J., & Lübbert, M. (2019) · Seminars in Hematology · doi:10.1053/j.seminhematol.2019.02.001 · Cited by 22 · see citing works

BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia

Vidal, V., Robert, G., Goursaud, L., Durand, L., Ginet, C., Karsenti, J. M., Luciano, F., Gastaud, L., Garnier, G., Braun, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17482 · Cited by 22 · see citing works

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia

Becker, H., Pfeifer, D., Ihorst, G., Pantić, M., Wehrle, J., Rüter, B. H., Bullinger, L., Hackanson, B. W., Germing, U., Kuendgen, A., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04082-7 · Cited by 21 · see citing works

The genetics of myelodysplastic syndromes and the opportunities for tailored treatments

Kontandreopoulou, C., Kalopisis, K., Viniou, N., & Diamantopoulos, P. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.989483 · Cited by 22 · see citing works

Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with <i>TP53</i> mutant MDS/AML

Sallman, D. A., Komrokji, R. S., Dezern, A. E., Sebert, M., Garcia‐Manero, G., Rahmé, R., Winer, E. S., Lehmann‐Che, J., Roboz, G. J., Madelaine, I., et al. (2025) · HemaSphere · doi:10.1002/hem3.70164 · Cited by 20 · see citing works

Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine

Bories, P., Prade, N., Lagarde, S., Cabarrou, B., Largeaud, L., Plenecassagnes, J., Luquet, I., Mas, V. M., Filleron, T., Cassou, M., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238795 · Cited by 20 · see citing works

TP53 in Myelodysplastic Syndromes

Jiang, Y., Gao, S., Soubise, B., Douet‐Guilbert, N., Liu, Z., & Troadec, M. (2021) · Cancers · doi:10.3390/cancers13215392 · Cited by 21 · see citing works

TP53 in AML and MDS: The new (old) kid on the block

Marks, J. A., Wang, X., Fenu, E. M., Bagg, A., & Lai, C. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101055 · Cited by 19 · see citing works

Genetic variants involved in oxidative stress, base excision repair, DNA methylation, and folate metabolism pathways influence myeloid neoplasias susceptibility and prognosis

Gonçalves, A. C., Alves, R., Baldeiras, I., Cortesão, E., Carda, J. P., Branco, C. C., Oliveiros, B., Loureiro, L., Pereira, A., Costa, N., et al. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22478 · Cited by 20 · see citing works

Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML

Kubasch, A. S., & Platzbecker, U. (2018) · Cancers · doi:10.3390/cancers10060158 · Cited by 20 · see citing works

The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia

Shallis, R. M., Boddu, P. C., Bewersdorf, J. P., & Zeidan, A. M. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100639 · Cited by 19 · see citing works

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Cluzeau, T., Loschi, M. L., Fenaux, P., Komrokji, R. S., & Sallman, D. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810105 · Cited by 19 · see citing works

From regulation to deregulation of p53 in hematologic malignancies: implications for diagnosis, prognosis and therapy

Ahmadi, S. E., Rahimian, E., Rahimi, S., Zarandi, B., Bahraini, M., Soleymani, M., Safdari, S. M., Shabannezhad, A., Jaafari, N., & Safa, M. (2024) · Biomarker Research · doi:10.1186/s40364-024-00676-9 · Cited by 22 · see citing works

Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study

Lee, B., Kang, K., Jeon, M. J., Yu, E. S., Kim, D. S., Choi, H., Lee, S. R., Sung, H. J., Kim, B. S., Choi, C. W., et al. (2020) · Scientific Reports · doi:10.1038/s41598-019-56642-1 · Cited by 19 · see citing works

Mutant p53-reactivating compound APR-246 synergizes with asparaginase in inducing growth suppression in acute lymphoblastic leukemia cells

Ceder, S., Eriksson, S. E., Liang, Y. Y., Cheteh, E. H., Zhang, S. M., Fujihara, K. M., Bianchi, J., Bykov, V. J. N., Abrahmsen, L., Clemons, N. J., et al. (2021) · Cell Death &amp; Disease · doi:10.1038/s41419-021-03988-y · Cited by 18 · see citing works

Nine years without a new FDA-approved therapy for MDS: how can we break through the impasse?

Dezern, A. E. (2015) · Hematology · doi:10.1182/asheducation-2015.1.308 · Cited by 18 · see citing works

Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia

Shapiro, R. M., & Lazo‐Langner, A. (2018) · BMC Hematology · doi:10.1186/s12878-017-0094-8 · Cited by 18 · see citing works

Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine

Desoutter, J., Gay, J., Berthon, C., Adès, L., Gruson, B., Geffroy, S., Plantier, I., Marceau‐Renaut, A., Hélevaut, N., Fernandes, J., et al. (2015) · Leukemia · doi:10.1038/leu.2015.314 · Cited by 17 · see citing works

Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia

Gopalakrishnapillai, A., Kolb, E. A., McCahan, S. M., & Barwe, S. P. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.05.004 · Cited by 17 · see citing works

Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine

Sébert, M., Komrokji, R. S., Sekeres, M. A., Prébet, T., Cluzeau, T., Santini, V., Gyan, E., Sanna, A., Ali, N. H. A., Hobson, S., et al. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.10.013 · Cited by 16 · see citing works

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes

McGraw, K. L., Cluzeau, T., Sallman, D. A., Basiorka, A. A., Irvine, B. A., Zhang, L., Epling‐Burnette, P. K., Rollison, D. E. M., Mallo, M., Sokol, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5255 · Cited by 15 · see citing works

p53 as an Effector or Inhibitor of Therapy ResponsePreprint

Ablain, J., Poirot, B., Esnault, C., Lehmann‐Che, J., & de Thé, H. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026260 · Cited by 15 · see citing works

How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes

Loschi, M. L., Fenaux, P., & Cluzeau, T. (2022) · Cancers · doi:10.3390/cancers14184519 · Cited by 15 · see citing works

A new prognostic index to make short-term prognoses in MDS patients treated with azacitidine: A combination of p53 expression and cytogenetics

Nishiwaki, S., Ito, M., Watarai, R., Okuno, S., Harada, Y., Yamamoto, S., Suzuki, K., Kurahashi, S., Iwasaki, T., & Sugiura, I. (2015) · Leukemia Research · doi:10.1016/j.leukres.2015.11.014 · Cited by 13 · see citing works

Decitabine treatment in 311 patients with acute myeloid leukemia: outcome and impact of TP53 mutations – a registry based analysis

Middeke, J. M., Teipel, R., Röllig, C., Stasik, S., Zebisch, A., Sill, H., Krämer, M., Scholl, S., Hochhaus, A., Jost, E., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1864354 · Cited by 13 · see citing works

How I treat higher-risk MDS

Mina, A. A., & Komrokji, R. S. (2025) · Blood · doi:10.1182/blood.2024025271 · Cited by 15 · see citing works

Potential use of compounds from sea cucumbers as MDM2 and CXCR4 inhibitors to control cancer cell growth

Wargasetia, T. L., Permana, S., & Widodo, N. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6588 · Cited by 12 · see citing works

Analysis of clinical and molecular features of MDS patients with complex karyotype in China

Ren, Y., Mei, C., Ye, L., Luo, Y., Zhou, X., Yang, H., Lin, P., Xu, W., Ma, L., Jin, J., et al. (2018) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2018.11.006 · Cited by 11 · see citing works

Prognostic Value of TP53 Gene Mutations in Higher Risk MDS Treated with Azacitidine

Bally, C., Adès, L., Renneville, A., Preudhomme, C., Mozziconacci, J., de Thé, H., Lehmann‐Che, J., & Fenaux, P. (2012) · Blood · doi:10.1182/blood.v120.21.1706.1706 · Cited by 5 · see citing works

Response To Azacitidine Is Independent Of TP53 Mutations In Higher-Risk Myelodysplastic Syndromes (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Müller‐Thomas, C., Rudelius, M., Rondak, I., Haferlach, T., Schanz, J., Schmidt, B., Kremer, M., Germing, U., Platzbecker, U., Peschel, C., et al. (2013) · Blood · doi:10.1182/blood.v122.21.2797.2797 · Cited by 2 · see citing works

P-006 Prognostic value of TP53 gene mutations in higher-risk MDS treated with azacitidine (AZA)

Bally, C., Adès, L., Renneville, A., Mozziconacci, J., Preudhomme, C., Dethé, H., Lehmann‐Che, J., & Fenaux, P. (2013) · Leukemia Research · doi:10.1016/s0145-2126(13)70055-9

PF553 CLONES WITH COMPLEX ABERRATIONS AND TP53 MUTATIONS RESPOND TO AZACITIDINE IN MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA

Ganster, C., Mazzeo, P., Elmaagacli, A. H., Dierks, S., Shirneshan, K., Scharnberg, P., Martin, R., Rittscher, K., Götze, K. S. S., Glaß, B., et al. (2019) · HemaSphere · doi:10.1097/01.hs9.0000560508.32787.fe

<i> <scp>TP</scp> 53 </i> mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis

Kulasekararaj, A. G., Smith, A. E., Mian, S. A., Mohamedali, A. M., Krishnamurthy, P., Lea, N. C., Gäken, J., Pennaneach, C., Ireland, R., Czepulkowski, B., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12203 · Cited by 250 · see citing works